Furthermore, METTL3 and YTHDF1 overexpression in HCC cells were required for the BM process, thus highlighting METTL3 and YTHDF1 as potential predictive biomarkers and therapeutic targets for HCC. This evidence concerns the gene METTL3 and hepatocellular carcinoma.